Journey Medical (DERM) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Journey Medical (DERM) is Neutral.

The composite score behind that read is -0.18, weighing +0.18 of bullish evidence against -0.29 bearish.

Journey Medical last closed at $6.69, +1.21% on the session.

Against the IVW growth benchmark the position is +0.29% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

6 graded predictions for DERM so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Journey Medical in the 27th percentile on return on equity, where 100 is best.

Journey Medical is classified under Health Care / Pharmaceuticals, with a market capitalisation of $146.90M.

StockMap tracks Journey Medical as the 85th largest of the 128 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 54 Moderate Underperform, 53 Neutral, 15 Strong Underperform and 6 Moderate Outperform.

On that composite Journey Medical ranks 55th of 128 in the group, against a group median of -0.24.